Kornimate/medical-research-clean huggingface dataset:
ultrasonic cardiogram evaluate the prognosis of percutaneous revascularization of chronic total occlusions

Conditions: Coronary Chronic Total Occlusion

Summary: chronic total occlusions (cto) are encountered in almost one-fourth of patients undergoing coronary angiography. the presence of an untreated cto has been related to adverse clinical prognosis, both in stable angina and acute myocardial infarction, and is often associated with persistent symptomatic angina. depending on their symptomatic and functional status as well as anatomical complexity, cto can be treated by optimal medical therapy only or therapy combined with coronary revascularization. this study designed to evaluate the safety and efficacy of coronary chronic total occlusion pci by ultrasonic cardiogram.

uceppcioct maintains a prospective clinical registry of all individual who undergo cardiac angiography,pci or optimistic medicine treatment. 1. research objective to observe the changes of cardiac function postoperative pci in patients with cto and the incidence of major adverse cardiovascular events, and provide the reality basis for pci strategy in clinical patients with cto . 2. research content: follow up the patients with cto by using echocardiography in preoperative and postoperative pci in 1m, 3ms, 6ms, 12ms to assess the changes of cardiac structure and cardiac function. 2, comparison the 'incidence of major adverse cardiovascular events undergo pci treatment in success and failure group in patients with cto (such as severe angina attack, severe acute coronary syndrome, severe heart failure should be rehospitalized , fatal arrhythmia and sudden cardiac death, etc.)

Eligibility criteria:
inclusion criteria: coronary artery of chronic total occlusion exclusion criteria: acs in 3months; once pci or cabg; af

Keywords: ultrasonic chronic total occlusion heart function
study on cognitive impairment of insomnia based on mri

Conditions: Insomnia; Cognitive Disorder; MRI

Summary: insomnia is a common sleep disorder. in recent years, the incidence of insomnia is increasing worldwide. studies point out that insomnia plays an important role in the pathogenesis of cognitive impairment. although sleep and cognitive scales are the main methods to detect sleep quality and cognitive changes, there are problems such as strong subjectivity and poor repetition. there is an urgent need to use non-invasive and objective detection methods to assess the potential mechanisms of cognitive impairment caused by sleep disorders. previous studies have shown that different brain states may show different neurovascular coupling (nvc) characteristics. however, after prolonged sleep deprivation, the evoked hemodynamics response was attenuated despite an increased electroencephalogram (eeg) signal response, suggesting that sustained neural activity may reduce vascular compliance. it is suggested that sleep disorder may lead to nvc disorder. however, whether sleep disorders regulate the mechanism of cognitive impairment in the brain through nvc disorders has not been demonstrated in vivo. currently, functional magnetic resonance imaging (fmri) can be used to study brain function and blood flow changes non-invasively. in our previous research, we combined cerebral blood flow (cbf) with mean amplitude of low-frequency fluctuation (malff), mean regional homogeneity (mreho) and degree-centrality (dc), the early warning effect of fmri features based on neurovascular uncoupling on early cognitive impairment was confirmed, providing a basis for further selection of functional imaging indicators. in conclusion, the present study proposes the scientific hypothesis that neurovascular decoupling-based mri features are more appropriate for exploring the neural mechanisms underlying sleep disorders-induced brain cognitive impairment. the aim of this study is to establish an early warning and monitoring system for early non-invasive diagnosis and intervention of sleep-related cognitive impairment.


Eligibility criteria:
inclusion criteria: * sleep score meets the group standard * education time more than 8 years * without dementia * inform consent form exclusion criteria: * pregnant woman * suffer from serious brain disease * magnetic resonance contraindications * image quality is too poor to deal with * lack of compliance
determination of molecular status, the efficacy and safety of fluorodeoxyglucose in pet-ct imaging

Conditions: Histiocytosis

Summary: prospective, low intervention, open, single-center, non-commercial clinical trial to improve diagnostics in patients with histiocytosis by assessing the molecular profile of the tumor tissues, monitoring its presence in free-circulating dna, and determining the efficacy of fluorodeoxyglucose (18f-fdg) in pet-ct imaging.

histiogen clinical study is part of the polhistio project. the polhistio project is a non-commercial clinical trial aimed at optimizing the diagnosis and treatment of juvenile patients with histiocytosis. the project objectives are defined as follows: 1) to estimate the nature and frequency of mutations in patients with histiocytosis in both tumor tissues and free-circulating dna; 2) to compare molecular test results with clinical data; 3) to evaluate the diagnostic usefulness of the status of molecular analysis (mrd) as a prognostic factor compared with other recognized factors. as part of the histiogen protocol, an immortalized cell line will be derived to study the pathogenesis of the disease, drug sensitivity, and drug resistance mechanisms. the project is intended to include patients from all over poland

Eligibility criteria:
inclusion criteria: 1. patient under 18 years of age at the time of inclusion. 2. histopathologically confirmed or suspected histiocytosis (based on prior test results). 3. signing of informed consent for trial participation according with current legal regulations. exclusion criteria: 1. lack of inclusion criteria. 2. pregnancy. 3. other acute or persistent disorders, behaviors or abnormal laboratory test results, which might increase the risk related to the participation in this clinical trial or to taking the study drug, or which might influence the interpretation of the study results, or which, in the investigator's opinion, disqualify a patient from participating in the trial.

Keywords: langerhans cell histiocytosis (lch) histiocytosis positron emission tomography (pet) molecular status paediatric patients
oral carnitine challenge test guides personalized nutrition for cv patients

Conditions: Dietary Modification; Cardiovascular Diseases

Summary: the investigators plan to use the recently developed oral carnitine challenge test (occt) as a tool to exam individual's trimethylamine n-oxide (tmao) production capacity from their gut microbiota. by using data collected by occt, the investigators defined subjects as high-tmao producer or low-tmao producer and apply low carnitine/choline diet as dietary intervention for the high-tmao producers. after dietary intervention for two months, the investigators conducted occt for the participants and compare the tmao production capacity before and after the dietary intervention.

patients diagnosed with cardiovascular disease at the cv clinics are being recruited to undergo the oral carnitine challenge test (occt) to assess the tmao production capacity of their gut microbiota. participants identified as high-tmao producers will be invited to partake in a two-month vegetarian diet intervention, supervised by a registered dietitian, followed by a three-month period of reverting to their regular diet. the occt will be conducted before and after the vegetarian diet intervention, as well as after the diet recovery phase. fecal samples will be collected and analyzed at the baseline, in the second month, and in the fifth month of the study.

Eligibility criteria:
inclusion criteria: * patient with risks of cardiovascular disease (cad) or cad patients proved by coronary angiography exclusion criteria: * age \< 20, hx of gi surgery, hx of malignancy, antibiotic or probiotic or carnitine supplement use within one month, liver cirrhosis, end stage chronic renal disease

Keywords: gut microbiota trimethylamine n-oxide oral carnitine challenge test cardiovascular disease
intravenous iron infusion on chemotherapy-induced anemia

Conditions: Colon Cancer; Chemotherapeutic-Induced Anemia

Summary: folfox, the first-line regimen based on 5-fu and oxaliplatin, is adjuvant chemotherapy for pathologic stage ii/iii colorectal cancer patients. among various side effects of folfox, chemotherapy-induced anemia occurs in about 30% of patients with folfox chemotherapy. an oral iron supplement is a widely accepted treatment for chemotherapy-induced anemia, but an oral iron supplement has a lot of inconveniences that can make patients' adherence worse, such as gastrointestinal discomfort, a long period of oral intake, and late recovery of serum iron level. intravenous iron infusion has been recently reported to be effective and safe to correct anemia. previous studies reported that intravenous iron is also effective to correct chemotherapy-induced anemia. however, there is a paucity of studies associated with colorectal cancer patients with folfox chemotherapy. this study aimed to evaluate the effect of intravenous iron on chemotherapy-induced anemia after folfox chemotherapy for patients with colorectal cancer compared with the effect of oral iron supplements. parameters including serum hb, serum iron, serum ferritin concentrations, total iron-binding capacity, absolute neutrophil count, platelet, albumin, c reactive protein, hepcidin, soluble transferrin receptor, and il6 will be analyzed. in addition, information on chemotoxicity, adverse events during chemotherapy and quality of life will be collected and analyzed.


Eligibility criteria:
inclusion criteria: * \* clinical diagnosis of stage ii or iii after curative resection for colon cancer and planned to be received modified folfox6 as an adjuvant chemotherapy * more than 18 years old * baseline hb level \<12g/dl or more hb 2g/dl decrease after chemotherapy * patients who received more than 1 cycle of folfox6 exclusion criteria: * \* patients with neoadjuvant therapy * patients who have other diseases associated with anemia such as ckd, ibd, other bone marrow diseases * patients who received rbc transfusion during chemotherapy * patients diagnosed with local recurrence or distant metastasis during chemotherapy * ferritin \> 800 ng/ml and tsat ≧ 50% * patients who are not willing to participate in the study
observational study of hunner's ulcer in patient with interstitial cystitis/bladder pain syndrome

Conditions: Interstitial Cystitis

Summary: the purpose of this study is to observe change of distribution pattern of hunner's ulcer in patient with interstitial cystitis/bladder pain syndrome

this is observational, 12 months study

Eligibility criteria:
inclusion criteria: 1. must have experienced bladder pain, urinary urgency and urinary frequency, for at least 6 months prior to entry into the study 2. pain vas ≥4 3. o'leary-sant interstitial cystitis questionnaire (ic-q) symptom and problem ≥ 12( and pain ≥2, and nocturia ≥ 2) 4. puf score ≥ 13 5. cystoscopic record within 2 years 6. hunner ulcer lesion in cystoscopic finding exclusion criteria: 1. scheduled for or use of intravesical therapy (eg, bladder distention,transurethral resection of bladder ulcer, instillation) during or within 6months prior to the study and use of pentosan polysulfate sodium within 1 months prior to the study 2. patients who are pregnancy or, childbearing age without no contraception 3. patients with voided volume \ 400ml 4. patients with microscopic hematuria, (≥1+ in dipstick), if not excluded that no evidence of neoplastic tumor examination 5. patients with urine culture showing evidence of urinary tract infection 1month prior to the study 6. accompanied medical problem below * tuberculosis in urinary system * bladder cancer, urethral cancer, prostate cancer * recurrent cystitis * anatomical disorder 7. patients had prior surgery (eq, bladder augmentation, cystectomy 8. patients with neurologic disorder 9. patients with indwelling catheter or intermittent self-catheterization 10. patients with psychologic problem
effects of exten(d) supplementation on training ability in recreational runners

Conditions: Joint Pain; Knee Inflammation; Biomechanical; Lesion

Summary: the study will assess running biomechanics and joint inflammation of physically active males between 40 and 60 years of age, mainly runners, suffering from knee joint inflammation and pain after training. participants were split into two groups, intervention and placebo, to evaluate the safety and efficacy of exten(d) supplementation during 4 weeks.

triple-blind, randomized, placebo-controlled, parallel group, pilot safety, and efficacy study. 30 healthy physically active males (40 to 60 years old) suffering from knee joint inflammation and pain after training were randomly assigned to the exten(d) or placebo group. during the first visit and after 4 weeks supplementation (either 2 g daily of exten(d) capsules or placebo capsules) the participants were subjected to a three-stage exercise session: (i) running biomechanical assessment, (ii) exercise physiology maximal effort test and (iii) running biomechanical assessment after the incremental exercise to exhaustion. the volunteers have been assessed to determine: (1) inflammation by i-r thermography and pain perception, (2) running technics though biomechanic analysis and (3) performance.

Eligibility criteria:
inclusion criteria: * male recreational runners who run for at least 150 minutes per week divided into two or more sessions. * the participants were expected to describe some degree of knee inflammation and/or discomfort after training in order to be accepted. knee discomfort was considered significant whenever a subject referred to a punctuation of ≥ 2 in a visual analogue scale (vas). * agree not to initiate any new exercise or diet programs during the entire study period * agree not to change their current diet or exercise program during the entire study period * agree not to stretch, utilize ice massage, take anti-inflammatory medications (eg, aspirin, ibuprofen), or use any other treatment during the trial. exclusion criteria: * use of anti-inflammatory medications or pain medications 1 week before the screening visit and during the study * daily use of dietary supplements and herbal supplements beginning at the screening visit and during the study * antibiotic use in the past 3 months * chronic disease

Keywords: harpagophytum zingiber officinae bixa orellana joint pain inflammation biomechanics
efficacy of pens of the auricle as an opioid sparing postoperative analgesic technique in cancer endometrium and cancer cervix patients

Conditions: Cancer of Endometrium; Cancer of Cervix

Summary: pain relief following laparotomy surgery requires a variety of techniques including invasive ones like epidural or nerve blocks along with different classes of drugs, out of which opioids are most predominant. each of these drugs have with their own set of advantages and also side effects. an ideal common system of analgesia is not possible due to patient variability. and no drug is devoid of side effects. hence the aim is to ensure effective analgesia using drugs or techniques which are minimally invasive with negligible side effects.

efficient post operative pain relief is an essential part of comprehensive recovery of patients. conventional method of pain management of laparotomy surgeries in ca endometrium and cervix patients involves invasive techniques like epidural or selective nerve block coupled with a varied choice of analgesics like opioids, nsaid or acetaminophen, wherein each drug is associated with its own set of contraindications and side effects. despite advances in analgesic regimen including multimodal analgesic regimen, opioids have been observed to remain the mainstay postoperative analgesia in cancer patients despite its well-established side effects. this double-blinded prospective interventional study is conducted to explore the alternative of percutaneous electrical nerve stimulation (pens) devices for effective pain relief with minimal to no side-effects. the device will have tiny needles and a battery system that will be placed on and behind the patient's ear when they are under anesthesia. it acts by stimulating nerves around ear region by series of pain free impulse generation leading to centrally (brain) mediated response by altering certain chemical substances responsible for causing pain thereby providing relief for the patient.

Eligibility criteria:
inclusion criteria: * age \>18 yrs * diagnosed with ca-endometrium or ca -cervix of stage i/ii and post rt ca cervix patients coming for hysterectomy * elective surgery * informed consent obtained * asa (american society of anaesthesiology) physical status 1-3 exclusion criteria: * patient refusal * cancer cervix other than the stages mentioned in inclusion criteria asa ps \>3 * emergency surgery, laparoscopic and robotic procedures * unplanned postoperative ventilation * allergy/sensitivity to adhesive * active skin infection/lesion in the ear region * h/o of seizure or cerebral disease * h/o chronic pain and prolonged analgesic usage * h/o opioid dependence * h/o anxiety or psychiatric illness requiring treatment * pre-existing implantable/ electronic on demand device * patients who might require mri in the study period * patients with transmissible diseases * patients with coagulopathies * absolute or relative contraindication to drugs used in the study
efficacy and safety of mbp8298 in subjects with secondary progressive multiple sclerosis

Conditions: Multiple Sclerosis, Secondary Progressive

Summary: this study will assess the efficacy and safety of mbp8298 compared to placebo in subjects with secondary progressive multiple sclerosis (spms)


Eligibility criteria:
inclusion criteria: * male of female subjects, 18-65 years of age with a diagnosis of spms * hla dr2 and/or dr4 positive * absence of a relapse in the 3 months prior to baseline * edss of 3.0 - 6.5 exclusion criteria: * therapy with beta-interferon, glatiramer acetate within 3 months or mitoxantrone, cyclophosphamide, methotrexate, azathioprine or any immune modulating or immunosuppressive drugs within 6 months of baseline * treatment with tysabri within 2 years of baseline * females who are breast feeding, pregnant (pregnancy test at baseline) or not using a medically approved method of contraception regularly other protocol-defined inclusion/exclusion criteria may apply.

Keywords: secondary progressive multiple sclerosis multiple sclerosis
assessment of the clinic-pathological correlation of basal cell carcinoma

Conditions: Basal Cell Carcinoma

Summary: assessment of the concordance of the initial clinical and histological diagnosis and to explore its prognostic impact in terms of risk of recurrence.

the skin cancer is a major public health problem whose incidence is increasing due to the aging population. among them, basal cell carcinoma (bcc) is a daily concern the dermatologist. the recommendation of good practice for the bcc of support has been established according to french agency methodology in 2004 : "agence nationale d'accréditation et d'evaluation en santé" (anaes). this classification is based on clinical and pathological use of sometimes mismatched terminology pretending to clinical reality with discrepancies between the clinical appearance and histology. on the other hand the simplified classification of recommendations has never been tested and validated on a large series of bcc. probabilistic margins applied based on clinical assessment of clinical and pathological subtype, it seems interesting to evaluate the consistency of the initial clinical diagnosis and histological diagnosis and to explore its prognostic impact in terms of risk of recurrence. this study could lead to improved clinical and pathological classification and allow amending the current recommendations of the surgical management of the bcc.

Eligibility criteria:
inclusion criteria: * primitive bcc * bcc clinically suspected or previously biopsied * supports conventional surgical or micrographic techniques. * patient able to sign a consent after reading the briefing note exclusion criteria: * recurrent cbc * prior medical treatment * bcc assigned to another operator for removal * genodermatosis underlying (xeroderma pigmentosum - gorlin syndrome)

Keywords: basal cell carcinoma, histological diagnosis, prognostic impact
a protein-sparing modified fast for children and adolescents with severe obesity (psmf)

Conditions: Obesity, Childhood

Summary: this is a 12 month prospective observational cohort study of the outpatient protein-sparing modified fast diet for children with severe obesity and serious comorbid condition(s). the study will enroll 30 center for healthy weight and nutrition patients aged 11-19 years who have been placed on a protein sparing modified fast as part of their treatment plan. the study-specific procedures consist of questionnaires/interviews on diet and pa behaviors, adherence and self-efficacy measures, data abstraction from the chart and tracking of activity using a fitbit.

aggressive dietary interventions may provide an accessible treatment option for children and adolescents with severe obesity who are not successful with traditional lifestyle behavioral interventions or do not want or qualify for weight loss surgery. one such intensive dietary option is the protein sparing modified fast (psmf). the psmf involves minimal carbohydrate intake to induce ketosis, while maintaining adequate or high protein intake to minimize catabolism. the psmf, under medical supervision, can be an effective and safe intervention for children and adolescents, yet the psmf diet is not regularly used in the treatment of pediatric severe obesity. this pilot study will employ a prospective cohort study design. thirty children, 11-19 years-old, with severe obesity, who have been prescribed the rpsmf as part of their treatment in a tertiary care pediatric weight management clinic (pwmc), will be recruited along with their attending parent to participate in the study. the primary aim of the study is to evaluate the acceptability of the rpsmf as assessed by adherence, satisfaction with the intervention, and participation rate using quantitative and qualitative methods. the secondary aim is to investigate the effectiveness of the rpsmf on improving a) anthropometric measures (weight, body mass index \[bmi\] and bmi z-score); b) metabolic measures (lipid profile, glycosylated hemoglobin, liver function tests); and c) quality of life. results of this study will provide guidance for the standardization of a pediatric rpsmf protocol in a clinic setting, delineate which factors improve or hinder adherence and weight loss and provide preliminary data for a multicenter randomized controlled trial.

Eligibility criteria:
inclusion criteria: * children age 11-19 years old * must be severely obese (bmi greater than or equal to 120% of the 95th percentile for their age and sex, or a bmi of 35 or greater) * must have at least one severe comorbidity * tanner stage iii, iv, v exclusion criteria: * non-english speaking * patients without adequate social/psychological capacity, as evidenced by unavailability to recourses, or family is unable to provide support.